Next Article in Journal
RFS+: A Clinically Adaptable and Computationally Efficient Strategy for Enhanced Brain Tumor Segmentation
Next Article in Special Issue
Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors
Previous Article in Journal / Special Issue
Comment on Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. Cancers 2023, 15, 4081
 
 
Reply
Peer-Review Record

Reply to Chen, A.; Zhang, X. Comment on “Golčić et al. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. Cancers 2023, 15, 4081”

Cancers 2023, 15(23), 5619; https://doi.org/10.3390/cancers15235619
by Marin Golčić 1,*, Robin L. Jones 2, Paul Huang 3 and Andrea Napolitano 2
Reviewer 1:
Reviewer 2:
Cancers 2023, 15(23), 5619; https://doi.org/10.3390/cancers15235619
Submission received: 9 November 2023 / Accepted: 15 November 2023 / Published: 28 November 2023
(This article belongs to the Special Issue Personalized Therapy of Sarcomas)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The response to comment if appriopriate in my opinion and should be accepted in present form

Reviewer 2 Report

Comments and Suggestions for Authors

Thank you for asking me to review this Author's reply. The author's reply is very helpful and I think justifys well the terminology used within the main paper, including the discussion about whether Imatinib dose escalation to 800mg should be considered second line therapy. I would strongly support publication of this reply to clarify this for the reader.

Back to TopTop